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Abstract
Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide1,2. 
Although 58 genomic regions have been associated with CAD to date3–9, most of the heritability 
is unexplained9, indicating additional susceptibility loci await identification. An efficient 
discovery strategy may be larger-scale evaluation of promising associations suggested by genome-
wide association studies (GWAS). Hence, we genotyped 56,309 participants using a targeted gene 
array derived from earlier GWAS results and meta-analysed results with 194,427 participants 
previously genotyped to give a total of 88,192 CAD cases and 162,544 controls. We identified 25 
new SNP-CAD-associations (P < 5x10-8, in fixed effects meta-analysis) from 15 genomic regions, 
including SNPs in or near genes involved in cellular adhesion, leucocyte migration and 
atherosclerosis (PECAM1, rs1867624), coagulation and inflammation (PROCR, rs867186 
[p.Ser219Gly]) and vascular smooth muscle cell differentiation (LMOD1, rs2820315). Correlation 
of these regions with cell type-specific gene expression and plasma protein levels shed light on 
potential novel disease mechanisms.
The CardioMetabochip is a genotyping array that contains 196,725 variants of confirmed or 
suspected relevance to cardiometabolic traits derived from earlier GWAS.10 A previous 
meta-analysis by the CARDIoGRAMplusC4D consortium of 79,138 SNPs common to the 
CardioMetabochip and GWAS arrays, identified 15 new loci associated with CAD3. Using 
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the CardioMetabochip, we genotyped 56,309 additional samples of European (EUR; ~52%), 
South Asian (SAS; ~23%), East Asian (EAS; ~17%) and African American (AA; ~8%) 
ancestries (Supplementary Information; Supplementary Tables 1, 2, 3; Supplementary Fig. 
1). The results from our association analyses of these additional samples were meta-analysed 
with those reported by CARDIoGRAMplusC4D at 79,070 SNPs in two fixed effects meta-
analyses, one in EUR participants and a second across all four ancestries (Figure 1 and 2). 
(Over-lapping samples were removed prior to meta-analysis [Methods]). A genome-wide 
significance threshold (P≤5x10-8 in the fixed effects meta-analysis) was adopted to minimise 
false positive findings. However, even at this strict P-value threshold, there is still a small 
chance of a false-positive result. The EUR fixed effects meta-analysis identified 15 SNPs 
associated with CAD at genome-wide significance (P<5x10-8) from nine distinct genomic 
regions that are not established CAD-associated loci (Table 1; Supplementary Table 4; 
Supplementary Fig. 2). An additional six distinct novel CAD-associated regions were 
identified in the all ancestries fixed effects meta-analysis (Table 1; Figure 2; Supplementary 
Table 4). In total, 15 novel CAD-associated genomic regions (25 SNPs) were identified 
(Supplementary Fig. 3 and 4). The lead SNPs had at least nominal evidence of association 
(P<0.05) in either a fixed effects meta-analysis of the EUR studies with de novo genotyping, 
or in a fixed effects meta-analysis of all the studies with de novo genotyping (Supplementary 
Table 5, Supplementary Fig. 5). Within the CARDIoGRAMplusC4D results for these SNPs, 
there was no evidence of heterogeneity of effects (P≥0.10) and allele frequencies were 
consistent with our EUR studies (Supplementary Table 5). Tests for enrichment of CAD-
associations within sets of genes11 and Ingenuity Pathway Analysis confirmed known CAD 
pathways (Supplementary Information; Supplementary Tables 6, 7, 8).
To prioritize candidate causal genes at the new loci, we defined regions encompassing the 
novel CAD-associated SNPs based on recombination rates (Supplementary Table 9) and 
cross referenced them with expression quantitative trait loci (eQTL) databases including 
GTEx12, MuTHER13 and STARNET14 (Methods). Twelve of the 15 novel CAD-associated 
SNPs were identified as potential eQTLs in at least one tissue (P<5x10-8; Table 2, 
Supplementary Table 10). Haploreg analysis15 (Methods) showed CAD-associated SNPs 
were enriched for H3K27ac enhancer marks (P < 5.1x10-4) in multiple heart related tissues 
(left ventricle, right atrium, aorta) in the EUR results and in one heart related tissue (right 
atrium) and liver in the all ancestry analyses (Supplementary Table 11). We next tested for 
protein quantitative trait loci (pQTL) in plasma on the aptamer-based Somalogic platform 
(Methods). Twenty-four proteins from the newly identified CAD regions were assayed and 
passed QC. Of our 15 novel CAD-associated SNPs, two associated with plasma protein 
abundance in trans: rs867186 (NP_006395.2:p.Ser219Gly), a missense variant in PROCR 
was a trans-pQTL for protein C (P=10-10, discussed below) and rs1050362 
(NP_054722.2:p.Arg140=) a synonymous variant in DHX38 was a trans-pQTL for the 
apolipoprotein L1 (P=5.37x10-29; Methods) which is suggested to interact with HPR in the 
DHX38 region (string database).
To further help prioritize candidate genes, we also queried the mouse genome informatics 
database to discover phenotypes resulting from mutations in the orthologous genes for all 
genes in our 15 CAD-associated regions (Table 2). To understand the pathways by which our 
novel loci might be related to CAD risk, we examined the associations of the 15 novel CAD 
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regions with a wide range of risk factors, molecular traits, and clinical disorders, using 
PhenoScanner16 (which encompasses the NHGRI-EBI GWAS catalogue and other 
genotype-phenotype databases).
Six of our loci have previously been associated with known CAD risk factors, such as major 
lipids (PCNX3,17 C12orf43/HNF1A, SCARB1, DHX38)18 and blood pressure (GOSR2,19 
PROCR20). The sentinel variants for the CAD and risk factor associations at PCNX3, 
GOSR2 and PROCR were the same, implicating them in known biological pathways. Two 
correlated SNPs (r2=0.93, D’=1.0 in 1000 genomes) rs11057830 and rs11057841 tag the 
CAD-association in the SCARB1 region (Table 1; Supplementary Table 4), a region reported 
previously to be associated with HDL (rs838876, β=-0.049, P=7.33x10-33)18. A rare 
nonsynonymous variant rs74830677 (NP_005496.4:p.Pro376Leu) in SCARB1 also 
associated with high levels of high-density lipoprotein cholesterol (HDL-C)21. Conditional 
analyses showed that the CAD-association was independent of the common variant HDL 
association (Supplementary Information, Supplementary Fig. 6). We found the CAD SNPs 
and the common HDL-C SNP, rs838880 overlap enhancers active in primary liver tissue 
(Supplementary Fig. 7). SCARB1 is highly expressed in liver and adrenal gland tissues 
(GTEx; Supplementary Fig. 7)12. These findings suggest that the discovered genetic 
variants most likely play a role in regulation of liver-restricted expression of SCARB1.
The DHX38 region has previously been associated with increased total and LDL 
cholesterol18. Both CAD-associated SNPs in DHX38, rs1050362 
(NP_054722.2:p.Arg140=) and rs2072142 (synonymous and intronic respectively; Table 1, 
Supplementary Table 4) are in LD but not strongly correlated with the previously reported 
cholesterol increasing SNP, intronic in HPR, rs2000999, (r2=0.41, D’=1 in 1000 Genomes 
EUR). Deletions in the HP gene have recently been shown to drive the reported cholesterol 
association in this region22. The CAD SNPs are in strong LD with SNPs that increase 
haptoglobin levels23 (rs6499560, P=2.92x10-13, r2=0.97), and haptoglobin has been 
reported to be associated with increased CAD risk24. HP encodes an alpha-2-glycoprotein 
which is synthesised in the liver. It binds free haemoglobin and protects tissues from 
oxidative damage. Mouse models indicate the role of Hp with development of 
atherosclerosis25, where the underlying mechanism is disruption of the protective nature of 
the Hp protein against hemoglobin-induced injury of atherosclerotic plaque. While the 
CAD-associated SNPs are eQTLs (or in LD with eQTLs) for multiple genes in the region 
e.g. DHODH in aorta artery12 (rs1050362 A allele, β=0.41, P=1.4x10-9), DHX38 in 
peripheral blood26, atherosclerotic aortic root14 (P<8x10-26; Table 2, Supplementary Table 
10), the A allele at rs1050362 is also associated with increased expression of HP in left 
ventricle heart (β=0.535, P=8.71x10-10)12 and decreased expression of HP in whole blood 
(β=-0.27, P=1.22x10-10)12. While there could be multiple causal genes in the region, 
together these findings suggest HP is a promising candidate gene.
PROCR encodes the endothelial protein C receptor (EPCR). We found the G allele at 
rs867186 (which codes for the glycine residue at p.Ser219Gly) in PROCR confers protection 
from CAD (OR[95%CI]=0.93[0.91-0.96]; Table 1, Supplementary Fig. 8). The same variant 
is also associated with increased circulating levels of soluble EPCR (which does not enhance 
protein C activation)27, increased levels of protein C28, increased factor VII levels29, and 
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increased risk of venous thrombosis27. Consistent with these associations, the variant has 
also been demonstrated to render the EPCR more susceptible to proteolytic cleavage, 
resulting in increased shedding of membrane-bound EPCR from the endothelial surface30 
causing elevated protein C levels in the circulation31. We found evidence of a second, 
independent CAD-association at rs6088590 (r2=0, D’=0.01 with rs867186 in 1000G EUR 
samples; Supplementary Fig. 8), an intronic SNP in NCOA6 with the T allele conferring 
increased risk of CAD (conditional on rs867186, conditional P=1.14x10-5, OR[95% 
CI]=0.97[0.95-0.98]). No additional SNPs were associated with CAD after conditioning on 
rs867186 and rs6088590 (P>0.01).
Five of the novel CAD regions identified in the current analysis include genes that encode 
proteins expressed in smooth muscle cells (LMOD1, SERPINH1, DDX59/CAMSAP2, 
TNS1, PECAM1)32,33. The CAD risk allele (T) of rs2820315, which is intronic in 
LMOD1, is associated with increased expression of LMOD1 in omental and subcutaneous 
adipose tissues13,34 (MuTHER, β=0.11, P=1.43x10-11). The protein is found in smooth 
muscle cells (SMC)32,33. In vitro and transgenic mouse studies demonstrate an essential 
requirement for CArG elements in the expression of LMOD1 through both serum response 
factor (SRF) and myocardin (MYOCD)35. Myocardin has emerged as an important 
molecular switch for the programs of SMC and cardiac myocyte differentiation36,37. The 
CAD-associated SNP (or tag) is an eQTL for IPO9 in peripheral blood mononuclear cells38, 
however, given the prior biological evidence LMOD1 would make the most plausible 
candidate gene.
rs1867624 is upstream of PECAM1, which encodes platelet/endothelial cell adhesion 
molecule 1, a protein found on platelet, monocyte and neutrophil surfaces. The C-allele is 
associated with reduced CAD risk (Table 1), increased expression of PECAM1 in peripheral 
blood mononuclear cells38 (β=0.1199, P=1.38x10-107) and is in LD with rs2070784 and 
rs6504218 (D’=1.0, r2>0.8 in 1000G EUR samples), which are eQTL for PECAM1 in aortic 
endothelial cells (P=4.35x10-13) and stimulated CD14+ monocytes39 respectively 
(P<1.7x10-24; Supplementary Table 10)39. PECAM-1 has been implicated in the 
maintenance of vascular barrier integrity, breach of which is a sign of inflammatory 
response. Failure to restore barrier function contributes to the development of chronic 
inflammatory diseases such as atherosclerosis. PECAM-1 expressing endothelial cell 
monolayers have been shown to exhibit increased steady-state barrier function, as well as 
more rapid restoration of barrier integrity following thrombin-induced perturbation 
compared to PECAM-1 deficient cells40. Expression of PECAM-1 has been shown to be 
correlated with increased plaque burden in athero-susceptible regions of the aorta in mice41 
and also with decreased atherosclerotic area in the aorta overall42. Together, these findings 
prioritise PECAM1 as a candidate causal gene for this CAD-associated region in humans.
Of the 58 previously established CAD loci3–9, 47 were included on the CardioMetabochip. 
Forty-five regions were directionally concordant with the previous reports (two were neutral) 
and thirty-four of these 45 (42 SNPs) had at least nominal evidence of association in a fixed 
effects meta-analysis (P<0.05) in either our EUR or all ancestry studies with de novo 
genotyping (Supplementary Table 12). Twenty-three of these formally replicated at a 
Bonferroni significance level P=0.05/47=0.001). PHACTR1, CXCL12 and COL4A1-
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COL4A2 had more statistical support of association (smaller P-values despite fewer 
samples) in SAS compared with the other ancestries. The PHACTR1 SNP, rs9349379, is 
ancestrally informative, as the A allele frequency ranges between 0.29 in the Taiwanese and 
0.91 in African Americans (Supplementary Table 12). In contrast, the COL4A1-COL4A2 
SNP, rs4773144, had similar allele frequencies across ancestries (EAF=0.56-0.62). The 
stronger effect size in SAS (OR[95%CI]=0.91[0.86-0.95] versus 0.98[0.95-1.02] in EUR, 
heterogeneity P=0.0042) could suggest gene-environment or gene-gene interactions at this 
locus.
We have reported 15 novel CAD-associations, which, together with previous efforts, brings 
the total number of CAD-associated regions to 73. In addition to implicating atherosclerosis 
and traditional risk factors as mechanisms in the pathobiology of CAD, our discoveries 
highlight the potential importance of biological processes active in the arterial wall involving 
endothelial, smooth muscle and white blood cells and promote coronary atherogenesis.
Online Methods
Study participants
A full description of the component studies with de novo genotyping is given in the 
Supplementary Information and Supplementary Table 1. In brief, the European (EUR) 
studies comprised 16,093 CAD cases and 16,616 controls from EPIC-CVD (a case-cohort 
study embedded in the pan-European EPIC prospective study), the Copenhagen City Heart 
Study (CCHS), the Copenhagen Ischemic Heart Disease Study (CIHDS) and the 
Copenhagen General Population Study (CGPS) all recruited within Copenhagen, Denmark. 
The South Asian (SAS) studies comprised up to 7,654 CAD cases and 7,014 controls from 
the Pakistan Risk of Myocardial Infarction Study (PROMIS) a case-control study that 
recruited samples from 9 sites in Pakistan, and the Bangladesh Risk of Acute Vascular 
Events (BRAVE) study based in Dhaka, Bangladesh. The East Asian (EA) studies comprised 
4,129 CAD cases and 6,369 controls recruited from 7 studies across Taiwan that collectively 
comprise the TAIwan metaboCHIp (TAICHI) Consortium. The African American (AA) 
studies comprised 2,100 CAD cases and 5,746 controls from the Atherosclerosis Risk in 
Communities Study (ARIC), Women’s Health Initiative (WHI) and six studies from the 
Myocardial Infarction Genetics Consortium (MIGen).
Ethical approval was obtained from the appropriate ethics committees and informed consent 
was obtained from all participants.
Genotyping and quality control in studies with de novo genotyping
Samples from EPIC-CVD, CCHS, CIHDS, CGPS, BRAVE and PROMIS were genotyped 
on a customised version of the Illumina CardioMetabochip (referred to as the “Metabochip
+”, Illumina, San Diego, USA), in two Illumina-certified laboratories located in Cambridge, 
UK, and Copenhagen, Denmark, by technicians masked to the phenotypic status of samples. 
The remaining studies were genotyped using the standard CardioMetabochip10 in Hudson-
Alpha and Cedars Sinai (TAICHI50, WHI, ARIC51) and the Broad Institute (MIGen).
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Each collection was genotyped and underwent QC separately (Supplementary Tables 1 and 
2). In brief, studies genotyped on the Metabochip+ had genotypes assigned using the 
Illumina GenCall software in Genome Studio. Samples were removed if they had a call rate 
< 0.97, average heterozygosity >±3 standard deviations away from the overall mean 
heterozygosity or their genotypic sex did not match their reported sex. One of each pair of 
duplicate samples and first degree relatives (assessed with a kinship co-efficient > 0.2) were 
removed.
Across all studies, SNP exclusions were based on minor allele frequency (MAF) < 0.01, P < 
1x10-6 for Hardy Weinberg Equilibrium or call rate (CR) less than 0.97 (full details are 
given in Supplementary Table 2). These exclusions were also applied centrally to studies 
genotyped on the CardioMetabochip, namely the ARIC, WHI, MIGen and TAICHI studies. 
Principal component analysis (PCA) was applied to identify and remove ancestral outliers. 
More stringent thresholds were adopted for SNPs used in the PCA for TAICHI and those 
studies genotyped on the Metabochip+, namely, CR < 0.99, PHWE < 1x10-4 and MAF < 
0.05. In addition, one of each pair of SNPs in LD (r2> 0.2) was removed, as were variants in 
regions known to be associated with CAD.
SNP association analyses and meta-analyses
Statistical analyses were performed in R or PLINK 52 unless otherwise stated.
We collected sufficient samples, to ensure the study was well powered to detect effect sizes 
in the range of OR=1.05-1.10 which have typically been reported for CAD. With 88,000 
cases the study would have 88% power to detect an OR=1.05 for a SNP with MAF=0.2 at 
α=5x10-8, assuming a multiplicative model on the OR scale. For a lower MAF of 0.1 the 
study would have 0.93 power to detect OR=1.07 at α=5x10-8, assuming a multiplicative 
model. Power calculations were performed using Quanto.
Association with CAD was assessed in studies with de novo genotyping from EUR, SAS, 
and EA, using the Genome-wide Efficient mixed model analysis (GEMMA) approach53. 
This model includes both fixed effects and random effects of genetic inheritance. CAD 
(coded 0/1) was the outcome variable, up to five principal components and the test SNP, 
coded additively, were included as fixed effects. P-values from the score test are reported. 
The AA studies were analysed using a logistic model in PLINK, with CAD as the outcome 
variable and SNP coded additively as predictor. The covariates used by each study, including 
the number of principal components are reported in the Supplementary Information. 
Genomic inflation was at most 5% for any given study (Supplementary Table 3, 
Supplementary Fig. 1). A subset of the PROMIS study and EPIC-CVD consortium were 
contributed to the CARDIoGRAMplusC4D 2013 report. To avoid any overlap of individuals 
in our studies with those in CARDioGRAMplusC4D, two analyses of these two studies were 
performed. One analysis included all the samples. A second analysis of the PROMIS and 
EPIC-CVD studies was performed after excluding all samples that had been contributed to 
the CARDIoGRAMplusC4D study and before meta-analyzing our results with the results 
from CARDIoGRAMplusC4D consortium. The CARDIoGRAMplusC4D SNP association 
results were converted onto the plus strand of GRh37, checked for heterogeneity and 
checked to ensure allele frequencies were consistent with EUR populations.
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Fixed effects inverse variance weighted meta-analysis was used to combine results across 
studies in METAL54. Heterogeneity P-values and I2 values were calculated and any SNP 
with P < 0.0001 for heterogeneity was removed. We performed two meta-analyses, the first 
involved just the European studies with de novo genotyping and the 
CARDIoGRAMplusC4D results to minimize ancestral diversity. The second involved all 
studies with de novo genotyping and the CARDIoGRAMplusC4D results to maximize 
sample size and statistical power. Given the ancestral diversity of the component studies 
with de novo genotyping, we also implemented meta-analyses with MANTRA55, a meta-
analysis approach designed to handle trans-ethnic study designs. However, for our studies 
the data were broadly consistent with the results from METAL (Table 1, Supplementary 
Table 4) and we therefore primarily report the fixed effect meta-analysis.
Conditional association analyses
Analyses to test for secondary association signals across seven regions with potential for 
independent signals were performed using GCTA56. GCTA implements a method for 
conducting conditional analyses using summary-level statistics (effect size, standard error, 
P-value, effective sample size) and LD information (r2) between SNPs estimated from a 
reference panel56. Conditional analyses were performed in CARDIoGRAMplusC4D, EUR, 
SAS, and EAS respectively and the results were combined using an inverse-variance-
weighted fixed effects meta-analysis approach. The conditional analyses were not performed 
in AA, because the SNP-level case-control counts were not made available for ARIC, 
MIGen, and WHI. 1000Genome Phase3 v5 ethnic-specific reference panel was used to 
provide LD information (r2) for the conditioned SNPs and other SNPs in the test regions for 
each of the 3 ancestries considered in the analyses. As approximately 9% of 
CARDIoGRAMplusC4D samples were SAS and the remainder EUR, in order to calculate 
LD for this dataset, we sampled with replacement the genotypes of 50 individuals from the 
1000Genome SAS reference panel and combined them with the genotypes of the 503 EUR 
individuals available in 1000 Genomes. To identify SNPs that are associated with CAD 
independently of the lead SNP in the test region, the association of each SNP in the region 
was tested conditioning on the most significant SNP in the overall meta-analysis of EUR, 
SAS, EAS and CARIoGRAMplusC4D. The SNPs were identified as independent signals for 
a specific region, if the conditional P≤1x10-4. In each region, we performed several rounds 
of conditional analyses until the conditional P-values >1x10-4 for all SNPs in the region.
eQTL and epigenetic analyses
The MuTHER dataset contains gene expression data from 850 UK twins for 23,596 probes 
and 2,029,988 (HapMap 2 imputed) SNPs. All cis–associated SNPs with FDR<1%, within 
each of the 14 newly identified CAD regions (IMPUTE info score >0.8) were extracted from 
the MuTHER project dataset for each of the tissues, LCL (n=777), adipose (n=776) and skin 
(n=667).
The GTEx Project provides expression data from up to 449 individuals for 52,576 genes 
annotated in Gencode v12 (including pseudo genes) and 6,820,472 genotyped SNPs (using 
the Human Omni5-Quad array).
Howson et al. Page 7
Nat Genet. Author manuscript; available in PMC 2018 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
From each resource, we report eQTL signals, which reach the resource-specific thresholds 
for significance described above, for SNPs that are in LD (r2>0.8) with our sentinel SNP.
In addition to the publicly available MuTHER and GTeX databases imputed to HapMap and 
1000Genomes, respectively, we used a curated database of over 100 distinct eQTL datasets 
to determine whether our lead CAD-associated SNPs or SNPs in high LD with them (r2 > 
0.8 in Europeans from HapMap or 1000G) were associated with the expression of one or 
more nearby genes in cis57. Our collated eQTL datasets meet criteria for statistical 
thresholds for SNP-gene transcript associations as described in the original studies. 57 In 
total, more than 30 different cells/tissues were queried including, circulating white blood 
cells of various types, liver, adipose, skin, brain, breast, heart and lung tissues. Complete 
details of the datasets and tissues queried in the current work can be found in the 
Supplement Information and Supplementary Table 10, and a general overview of a subset of 
over 50 eQTL studies has been published57. We first identified all sets of eQTLs in perfect 
LD (r2=1 among Europeans in HapMap or 1000G) with each other for each unique 
combination of study, tissue, and transcript. We then determined whether any of these sets of 
eQTL were either in perfect (r2 = 1) or high LD (1>r2> 0.8) with our lead CAD SNP 
(Supplementary Table 10).
We required that any eQTL had P<5x10-8 for association with expression levels to be 
included in the eQTL tables.
We examined chromatin state maps of 23 relevant primary cell types and tissues. Chromatin 
states are defined as spatially coherent and biologically meaningful combinations of specific 
chromatin marks. These are computed by exploiting the correlation of such marks, including 
DNA methylation, chromatin accessibility, and several histone modifications58,59.
pQTL analyses
We conducted plasma protein assays in 3,301 healthy blood donors from the INTERVAL 
study60 who had all been genotyped on the Affymetrix Axiom UK Biobank genotyping 
array and imputed to a combined 1000Genomes + UK10K haplotype reference panel61. 
Proteins were assayed using the SomaLogic SomaScan platform, which uses high-specificity 
aptamer-binding to provide relative protein abundances. Proteins passing stringent QC (e.g. 
coefficient of variation<20%) were log transformed and age, sex, duration between 
venepuncture and sample processing and the first 3 principal components of genetic ancestry 
were regressed out. Residuals were then rank-inverse normalized before genomewide 
association testing using an additive model accounting for imputation uncertainty.
Enrichment analyses
Ingenuity pathway analyses—We used the Core Analysis' function in the Ingenuity 
Pathway Analysis (IPA) software (Ingenuity Systems, Redwood City) to identify canonical 
pathways enriched with one or more SNPs with a low P-value in the all ancestry meta-
analysis.
Modified MAGENTA—Given the Metabochip comprises a select set of SNPs and lacks 
complete genomic coverage10, MAGENTA, which assumes random sampling of variants 
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from across the genome, could not be directly implemented. Therefore a modified version of 
MAGENTA involving a hypergeometric test to account for the chip design was used to test 
for pathways that were enriched with CAD-associated variants11. This approach requires 
defining two sets of variants; a null set of variants that are not associated with CAD and a set 
that are associated with CAD, referred to as the “associated set”. Multiple variants can map 
to the same gene and still be included in the test. SNPs in LD were pruned out of the 
association results such that r2 < 0.2 for all pairs of SNPs (based on 1,000 Genomes Project 
data62; Supplementary Table 6) prior to implementation of the modified MAGENTA. The 
null set was defined as the 1,000 remaining QT interval SNPs with the largest P-values (least 
evidence) for association with CAD. The associated set was defined as variants (after LD 
pruning) that showed evidence of association P < 1x10-6. This approach was adopted to 
select the null and associated sets so as to limit the number of variants included in the 
hypergeometric cumulative mass function, as a large number of variants results in an 
intractable calculation for the binomial coefficients. The observed P-value from the 
hypergeometric test is compared to the P-values obtained from 10,000 random sets to 
compute an empirical enrichment P-value.
Haploreg: H3K27ac-based tissue enrichment analysis—The associated set as 
defined for MAGENTA was used for Haploreg analyses and compared to a background set 
of 12,000 SNPs previously associated with any trait at P<1x10-5 (taken from sources such as 
NHGRI-EBI GWAS catalogue). Using data from HaploReg15 we counted the number of 
SNPs with an H3K27ac annotation, or in high LD (r2 > 0.8 from the SNiPA63 EUR 1000 
Genomes maps) with a SNP with an H3K27ac annotation. The significance of the 
enrichment in H3K27ac marks from a particular tissue was determined by comparing the 
fraction of associated SNPs with that mark, to the fraction of background SNPs with that 
same mark. A hypergeometric test was used to assign a P-value to the enrichment.
Data availability—The full set of results data from the trans-ancestry meta-analysis and 
the EUR meta-analysis from this report is available through 
www.phenoscanner.medschl.cam.ac.uk upon publication.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Schematic of the study design. The sample-size information is provided as number of cases/
number of controls. Note, samples with de novo genotyping that were also in the 
CARDIoGRAMplusC4D study were removed prior to meta-analysis.* 1,826 CAD cases and 
449 controls from EPIC-CVD with de novo genotyping were also included in 
CARDIoGRAMplusC4D and were therefore excluded from the larger meta-analysis. The 
actual number of EUR individuals contributed to the meta-analysis of our studies with de 
novo genotyping and CARDIoGRAMplusC4D was 14,267 CAD cases and 16,167 
controls.†3,704 CAD cases and 3,433 controls from PROMIS with de novo genotyping were 
also included in CARDIoGRAMplusC4D and were therefore excluded from the larger meta-
analysis. The actual number of SAS samples contributed to the meta-analysis of our studies 
with de novo genotyping and CARDIoGRAMplusC4D was 3,950 CAD cases and 3,581 
controls.
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Figure 2. 
Plot showing the association of ~79,000 variants with CAD (-log10P-value) in up to 88,192 
cases and 162,544 controls from the all ancestry fixed effects meta-analysis. SNPs are 
ordered in physical position. No adjustments to P-values to account for multiple testing have 
been made. The outer track represents the chromosomal number. Blue dots represent known 
loci and red dots are the new loci identified in the current study. Each association peak is 
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labeled with the name of the closest gene(s) to the sentinel SNP. GWAS significance (-
log10(P) ~ 7.3).
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